Biotechnology First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline – First Wave BioPharma (NASDAQ:FWBI) Read more